Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Operating activities:
Net loss	$ (135,996)	$ (116,591)
Reconciliation of net loss to net cash used in operating activities:
Depreciation and amortization	4,736	4,833
Equity-based compensation	20,212	19,405
Other non-cash items, net	2,253	(8,385)
Changes in:
Accounts receivable	25,000	200,000
Prepaid expenses and other assets	(634)	2,949
Accounts payable and accrued expenses	42,998	9,443
Deferred revenue	(824)	(504)
Operating lease assets and liabilities	(1,151)	(966)
Other liabilities, net	(10,541)	(432)
Net cash (used in) provided by operating activities	(53,947)	109,752
Investing activities:
Purchase of property, plant and equipment	(206)	(721)
Investment in equity securities	(5,000)	(7,500)
Purchases of marketable securities	(200,730)	(326,915)
Maturities of marketable securities	186,181	237,336
Net cash used in investing activities	(19,755)	(97,800)
Financing activities:
Proceeds from issuance of common shares, net of issuance costs	8,516	280,745
Proceeds from exercise of options and ESPP contributions, net of issuance costs	2,072	25,189
Net cash provided by financing activities	10,588	305,934
Effect of exchange rate changes on cash	41	(11)
(Decrease) increase in cash	(63,073)	317,875
Cash, cash equivalents and restricted cash, beginning of period	309,776	401,068
Cash, cash equivalents and restricted cash, end of period	246,703	718,943
Supplemental disclosure of non-cash investing and financing activities
Equity issuance costs in accounts payable, accrued expenses, and other long-term liabilities	$ 3,219	$ 4,522